A jolt to the brain may unlock words: testing tDCS for language in down syndrome

NCT ID NCT07044804

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether a gentle electrical current applied to the brain, called transcranial direct current stimulation (tDCS), can boost language skills in adolescents and young adults with Down syndrome when paired with speech therapy. Thirty-six participants aged 12 to 21 will receive either active tDCS (anodal or cathodal) or a sham version over 10 sessions. The goal is to see if the stimulation improves expressive vocabulary and other language abilities, and whether any benefits last for three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS) applied to the left inferior frontal gyrus, combined with speech and language training
What this could lead to
If effective, this approach could offer a new, non-invasive rehabilitation strategy to improve language abilities in adolescents and young adults with Down syndrome.
What could go wrong
This is a small, early proof-of-concept study with only 36 participants. It is unclear whether tDCS will produce lasting benefits, and individual responses may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Italian speakers participants of both genders with the presence of a free trisomy 21 documented by karyotyping 2. Adolescents and young adults from 12 to 21 years old 3. Mental age ≥ 4 years (as assessed by Leiter-3 at baseline) 4. Scores \< 2 SD at the denomination subtest of BVL\_4-12 5. Be comprehensible to closest relatives, at least in part, exhibiting consistent speech sounds mesured by Intelligibility in Context Scale (ICS): Italian (McLeod, Harrison, \& McCormack, 2012) with a cut-off of 3.5 6. Informed consent/absent from each patient and Informed consent from their caregivers. Exclusion Criteria: 1. The presence of any neurosensory deficits, such as hypoacusis or serious visual impairments 2. The presence of epilepsy, familiarity with epilepsy and major psychopathological disorders 3. Scores \< 10 points at the denomination subtest of BVL\_4-12 4. Ability to verbally imitate less that 7 of 10 words during an imitation screening task 5. Undergoing concomitant speech therapy or psychopharmacological therapy for cognitive or behavioral improvement.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Down syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bambino Gesù Children's Hospital, IRCCS

    RECRUITING

    Rome, 00165, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.